

Figure 1





Figure 1 cont.






Figure 2




Figure 3




Figure 3 cont.






Figure 3 cont.



F



E





Figure 4
A



9/51

Figure 4 cont.



B**C**

Figure 5




Figure 5 cont.




Figure 5 cont.

D





	G0	G1	G2	mitosis
				
Ki-67 staining pattern		Group A (DCCD≤100) n cells	Group B (DCCD>100) n cells	
Mitosis		3 (1.4%)	46 (6.3%)	
Early G1		8 (3.8%)	68 (9.4%)	
G2		13 (6.2%)	46 (6.3%)	
G0		186 (88.6%)	567 (78.0%)	
n MelanA+ cells		210 (100%)	727 (100%)	
n lymphnodes (cells/lymphnode)		37 (1-28)	21 (10-50)	

Figure 6




Figure 6 cont.

D

Patient ID	BRAF		9p11-13 loss		9p21-24		7q21-36		NRAS	
	DCC	PDX	DCC	PDX	DCC	PDX	DCC	PDX	DCC	PDX
125	wt	wt	balan.	balan.	loss	gain	balan.	loss	mut	mut
135	mut	mut	balan.	balan.	loss	loss	gain	gain	wt	wt
154	mut	mut	na	balan.	na	loss	na	gain	wt	wt
155	mut	mut	balan.	balan.	loss	loss	gain	gain	wt	wt




Figure 7






Figure 8

2316 KMN1**2349 KMN1**

17/51

Figure 8 cont.



2337 KMN1**2349 KMN2**

Figure 8 cont.



2436 KMN1**2436 LKN1**

Figure 8 cont.



2436 KMN2**2501 KMN1**

Figure 8 cont.



3214 LKN1**3425 KMN1**

Figure 8 cont.



3596 KMN1**778 NZ1**

Figure 8 cont.



3641 KMN2**778 NZ2**

Figure 8 cont.





1032 NZ1**1032 NZ2**

Figure 8 cont.

1077 NZ2


25/51

Figure 8 cont.

LK 16 N2

26/51

Figure 8 cont.

LK 16 N1

27/51

Figure 8 cont.




LK 16 N3

Figure 8 cont.

RPC 94 N


29/51

Figure 8 cont.

114 N


30/51

Figure 8 cont.
856-3b




31/51

Figure 8 cont.

983-9SMb16

32/51

Figure 8 cont.

741-9SMb

33/51

Figure 8 cont.




PBL SC 1

Figure 8 cont.

PBL SC 2


35/51

Figure 8 cont.

PBL SC 3

36/51

Figure 8 cont.

PBL SC 4

37/51

Figure 8 cont.



PBL SC 5

Figure 9



39/51

Figure 10




Figure 11




Figure 12




Figure 13




Figure 13 cont.




Figure 13 cont.




Figure 14




Table 1

Baseline characteristics of melanoma patients.

	number of patients	percentage [%]	median	range	interquartile range
gender					
female	25	41			
male	36	59			
age [years]			61	20 - 78	47.5 - 70
Breslow's thickness [mm]			2.35	0.6 - 10.0	1.3 - 4.08
Ulceration					
no	39	63.9			
yes	19	31.2			
not specified	3	4.9			
localization					
extremities	32	52.5			
trunk or head	29	47.5			
nodal status histopathology					
negative	37	60.7			
positive	24	39.3			
DCCD			32	1 - 800000	3 - 177
clinical stage					
IA	4	6.5			
IB	15	24.6			
IIA	7	11.5			
IIB	5	8.2			
IIC	2	3.3			
IIIA	11	18.0			
IIIB	13	21.3			
IIIC	4	6.5			

47/51

Figure 15

A




Figure 15

B




Figure 15

B cont.




Figure 16





Figure 16 cont.



score = % IFN γ ⁺ cells x ratio MFI IFN γ ⁺ cells of PD1^{hi}/ MFI IFN γ ⁺ cells of PD-1^{int} x ratio %PD-1^{int}neg/%PD^{-high}